-+ 0.00%
-+ 0.00%
-+ 0.00%

Cabaletta Bio Outlines 2026 Strategy Focused on Enrolling Pivotal Myositis Trial, Advancing Outpatient and No Preconditioning Rese-cel Therapies, and Scaling Automated Manufacturing for Autoimmune Disease Pipeline

Reuters·01/12/2026 13:00:13

Please log in to view news